文献速递乳腺癌头颈与中枢神经肿瘤

TBCRC 022:来那替尼联合卡培他滨治疗人表皮生长因子受体2阳性乳腺癌脑转移患者的II期试验

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
PubMed 文献 · J Clin Oncol · 2019-03-12

该II期试验评估来那替尼联合卡培他滨治疗可测量、进展性HER2阳性乳腺癌脑转移患者的疗效,纳入来那替尼初治(队列3A,n=37)和经拉帕替尼治疗(队列3B,n=12)患者。队列3A复合中枢神经系统客观缓解率为49%(95%CI 32%至66%),队列3B为33%(95%CI 10%至65%);中位无进展生存期分别为5.5和3.1个月,中位生存期分别为13.3和15.1个月。

要点

  • 来那替尼联合卡培他滨对难治性HER2阳性乳腺癌脑转移有活性。
  • 队列3A复合CNS ORR为49%(95%CI 32%至66%)。
  • 腹泻是最常见3级毒性,队列3A和3B均为29%。

核心结论

  • 来那替尼联合卡培他滨对难治性HER2阳性乳腺癌脑转移有活性,为HER2靶向治疗在脑内疗效可被化疗增强增添了证据。
  • 为获得最佳耐受性,有必要努力减少腹泻。

研究设计与样本

  • II期试验纳入可测量、进展性HER2阳性乳腺癌脑转移患者,92%在接受CNS手术和/或放疗后。
  • 来那替尼240 mg口服每日一次联合卡培他滨750 mg/m2每日两次,用药14天、停7天。
  • 来那替尼初治患者入队列3A,经拉帕替尼治疗患者入队列3B。
  • 主要终点为各队列分别的复合CNS客观缓解率,要求靶CNS病灶体积总和减少50%或以上,且无非靶病灶进展、新病灶、类固醇升级、进展性神经体征或症状或非CNS进展。
  • 队列3A(n=37)和队列3B(n=12;因入组缓慢关闭)共49例患者入组。

主要发现

  • 队列3A复合CNS ORR为49%(95%CI 32%至66%)。
  • 队列3B CNS ORR为33%(95%CI 10%至65%)。
  • 队列3A和3B中位无进展生存期分别为5.5和3.1个月。
  • 队列3A和3B中位生存期分别为13.3和15.1个月。
  • 腹泻是最常见3级毒性,队列3A和3B均为29%。

关键数值与推荐

  • 若队列3A 35例中9例或以上、或队列3B 25例中3例或以上达到CNS客观缓解,则该联合方案被认为有前景。
  • 复合CNS客观缓解要求靶CNS病灶体积总和减少50%或以上,且无非靶病灶进展、新病灶、类固醇升级、进展性神经体征或症状或非CNS进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 队列3B因入组缓慢关闭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS: Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS: Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). UNLABELLED: Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019. PMID: 30860945. doi:10.1200/JCO.18.01511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。